Participant-Centred Recruitment and Retention: Driving Faster Answers in Clinical Trials

Winter 2025 Issue – Journal for Clinical Studies

Richmond Pharmacology is proud to announce the publication of an editorial by Elizabeth Romano, Director of Communications and Participant Engagement, in the Winter 2025 issue of the Journal for Clinical Studies.

The article explores participant‑centred recruitment and retention strategies, emphasising how placing participants at the heart of trial design improves engagement, retention, and data quality. At Richmond, we translate these principles into action every day: by leveraging our extensive volunteer database, offering flexible scheduling, and providing dedicated participant support, we ensure trials can start and progress faster — delivering faster answers for sponsors.

Key themes from the article include:

  • Recruitment as a journey: Awareness, clarity, and trust shape participation long before enrolment.
  • Reducing participant burden: Decentralised visits, flexible appointments, and responsive support increase engagement.
  • Inclusivity and patient involvement: Embedding patient and public involvement (PPI) ensures trials are equitable and robust.

"Treating recruitment and retention as strategic priorities strengthens adherence, improves data quality, and accelerates study timelines."

Read the full article here: Recruitment and Retention in Clinical Trials: A Participant-Centred Approach - Journal for Clinical Studies

Latest news

Participant-Centred Recruitment and Retention: Driving Faster Answers in Clinical Trials.

December 18, 2025
Richmond Pharmacology is proud to announce the publication of an editorial by Elizabeth Romano, Director of Communications and Participant Engagement, in the Winter 2025 issue of the Journal for Clinical Studies.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event